5-HT2 receptors facilitate JC polyomavirus entry

Journal of Virology

Volumn 87, Issue 24, 2013, Pages 13490-13498

  Assetta, Benedetta ^a   Maginnis, Melissa S ^b   Ahufinger, Irene Gracia ^c   Haley, Sheila A ^b   Gee, Gretchen V ^b   Nelson, Christian D S ^b   O'Hara, Bethany A ^b   Allen Ramdial, Stacy Ann A ^b   Atwood, Walter J ^b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; LACTOSERIES TETRASACCHARIDE C; PENTASACCHARIDE; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; SEROTONIN;

ARTICLE; CELL STRAIN; CELL STRAIN HEK293A; CONTROLLED STUDY; HUMAN; HUMAN CELL; JC VIRUS; NONHUMAN; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; VIRUS CELL INTERACTION; VIRUS ENTRY; CELL STRAIN HEK293; GENETICS; METABOLISM; PHYSIOLOGY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VIROLOGY; HEK293 CELL LINE;

HEK293 CELLS; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN; VIRUS INTERNALIZATION;

EID: 84888048177     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02252-13     Document Type: Article

References (72)

1. Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH. 2009. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J. Infect. Dis. 199:837-846.
2. Viscidi RP, Rollison DE, Sondak VK, Silver B, Messina JL, Giuliano AR, Fulp W, Ajidahun A, Rivanera D. 2011. Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin. Vaccine Immunol. 18:1737-1743.
3. Chang H, Wang M, Tsai RT, Lin HS, Huan JS, Wang WC, Chang D. 2002. High incidence of JC viruria in JC-seropositive older individuals. J. Neurovirol. 8:447-451.
4. Arthur RR, Dagostin S, Shah KV. 1989. Detection of BK virus and JC virus in urine and brain tissue by the polymerase chain reaction. J. Clin. Microbiol. 27:1174-1179.
5. Coleman DV, Wolfendale MR, Daniel RA, Dhanjal NK, Gardner SD, Gibson PE, Field AM. 1980. A prospective study of human polyomavirus infection in pregnancy. J. Infect. Dis. 142:1-8.
6. Flaegstad T, Sundsfjord A, Arthur RR, Pedersen M, Traavik T, Subramani S. 1991. Amplification and sequencing of the control regions of BK and JC virus from human urine by polymerase chain reaction. Virology 180:553-560.
7. Myers C, Frisque RJ, Arthur RR. 1989. Direct isolation and characterization of JC virus from urine samples of renal and bone marrow transplant patients. J. Virol. 63:4445-4449.
8. Markowitz RB, Thompson HC, Mueller JF, Cohen JA, Dynan WS. 1993. Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and-uninfected subjects. J. Infect. Dis. 167:13-20.
9. McQuaig SM, Scott TM, Lukasik JO, Paul JH, Harwood VJ. 2009. Quantification of human polyomaviruses JC virus and BK virus by TaqMan quantitative PCR and comparison to other water quality indicators in water and fecal samples. Appl. Environ. Microbiol. 75:3379-3388.
10. Hamza IA, Jurzik L, Stang A, Sure K, Uberla K, Wilhelm M. 2009. Detection of human viruses in rivers of a densly-populated area in Germany using a virus adsorption elution method optimized for PCR analyses. Water Res. 43:2657-2668.
11. Ahmed W, Wan C, Goonetilleke A, Gardner T. 2010. Evaluating sewageassociated JCV and BKV polyomaviruses for sourcing human fecal pollution in a coastal river in Southeast Queensland, Australia. J. Environ. Qual. 39:1743-1750.
12. Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, Roberts JR, Gitt J, Saini N, Lux W. 1988. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N. Engl. J. Med. 318:301-305.
13. Major EO, Amemiya K, Elder G, Houff SA. 1990. Glial cells of the human developing brain and B cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus, JCV. J. Neurosci. Res. 27:461-471.
14. Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. 1996. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells:implications for viral latency. J. Virol. 70:7004-7012.
15. Berger JR, Miller CS, Mootoor Y, Avdiushko SA, Kryscio RJ, Zhu H. 2006. JC virus detection in bodily fluids:clues to transmission. Clin. Infect. Dis. 43:e9-e12.
16. Monaco MC, Shin J, Major EO. 1998. JC virus infection in cells from lymphoid tissue. Dev. Biol. Stand. 94:115-122.
17. Chapagain ML, Nerurkar VR. 2010. Human polyomavirus JC (JCV) infection of human B lymphocytes:a possible mechanism for JCV transmigration across the blood-brain barrier. J. Infect. Dis. 202:184-191.
18. Tan CS, Ellis LC, Wuthrich C, Ngo L, Broge TA, Jr, Saint-Aubyn J, Miller JS, Koralnik IJ. 2010. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J. Virol. 84:9200-9209.
19. Perez-Liz G, Del Valle L, Gentilella A, Croul S, Khalili K. 2008. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann. Neurol. 64:379-387.
20. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. 1971. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet i:1257-1260.
21. Budka H, Shah KV. 1983. Papovavirus antigens in paraffin sections of PML brains. Prog. Clin. Biol. Res. 105:299-309.
22. Berger JR, Khalili K. 2011. The pathogenesis of progressive multifocal leukoencephalopathy. Discov. Med. 12:495-503.
23. Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO. 2012. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin. Microbiol. Rev. 25:471-506.
24. Major EO. 2010. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61:35-47.
25. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL. 2009. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients:a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834-4840.
26. Kleinschmidt-DeMasters BK, Tyler KL. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353:369-374.
27. Engelhardt B, Kappos L. 2008. Natalizumab:targeting alpha4-integrins in multiple sclerosis. Neurodegener. Dis. 5:16-22.
28. Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ. 2013. JC virus antibody status underestimates infection rates. Ann. Neurol. 74:84-90.
29. Steiner I, Berger JR. 2012. Update on progressive multifocal leukoencephalopathy. Curr. Neurol. Neurosci. Rep. 12:680-686.
30. Johnson T, Nath A. 2011. Immune reconstitution inflammatory syndrome and the central nervous system. Curr. Opin. Neurol. 24:284-290.
31. Berger JR. 2011. The clinical features of PML. Cleve. Clin. J. Med. 78(Suppl 2):S8-S12.
32. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. 2010. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat. Rev. Neurol. 6:667-679.
33. Neu U, Maginnis MS, Palma AS, Stroh LJ, Nelson CD, Feizi T, Atwood WJ, Stehle T. 2010. Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe 8:309-319.
34. Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ. 2004. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306:1380-1383.
35. Maginnis MS, Haley SA, Gee GV, Atwood WJ. 2010. Role of N-linked glycosylation of the 5-HT2A receptor in JC virus infection. J. Virol. 84:9677-9684.
36. Chapagain ML, Verma S, Mercier F, Yanagihara R, Nerurkar VR. 2007. Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A. Virology 364:55-63.
37. O'Hara BA, Atwood WJ. 2008. Interferon beta1-a and selective anti-5HT(2a) receptor antagonists inhibit infection of human glial cells by JC virus. Virus Res. 132:97-103.
38. Croom KF, Perry CM, Plosker GL. 2009. Mirtazapine:a review of its use in major depression and other psychiatric disorders. CNS Drugs 23:427-452.
39. Cervantes-Duran C, Pineda-Farias JB, Bravo-Hernandez M, Quinonez-Bastidas GN, Vidal-Cantu GC, Barragan-Iglesias P, Granados-Soto V. 3 December 2012. Evidence for the participation of peripheral 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptors in formalin-induced secondary mechanical allodynia and hyperalgesia. Neuroscience pii:S0306-4522(12)01158-X. [Epub ahead of print.] doi:10.1016/j.neuroscience.2012.11.047.
40. Peroutka SJ. 1994. Molecular biology of serotonin (5-HT) receptors. Synapse 18:241-260.
41. Korstanje C, Sprenkels R, Doods HN, Hugtenburg JG, Boddeke E, Batink HD, Thoolen MJ, Van Zwieten PA. 1986. Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in-vivo alpha 1-,alpha 2-and 5-HT2-receptor antagonism and in-vitro affinity for alpha 1-,alpha 2-and 5-HT2-receptors:comparison with ketanserin. J. Pharm. Pharmacol. 38:374-379.
42. Park JH, Ryoo S, Noh HJ, Seo JM, Kang HH, Shin JS, Seo SW, Na DL. 2011. Dual therapy with cidofovir and mirtazapine for progressive multifocal leukoencephalopathy in a sarcoidosis patient. Case Rep. Neurol. 3:258-262.
43. Lanzafame M, Ferrari S, Lattuada E, Corsini F, Deganello R, Vento S, Concia E. 2009. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez. Med. 17:35-37.
44. Cettomai D, McArthur JC. 2009. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch. Neurol. 66:255-258.
45. Verma S, Cikurel K, Koralnik IJ, Morgello S, Cunningham-Rundles C, Weinstein ZR, Bergmann C, Simpson DM. 2007. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J. Infect. Dis. 196:709-711.
46. Iannetta M, Bellizzi A, Lo Menzo S, Anzivino E, D'Abramo A, Oliva A, D'Agostino C, d'Ettorre G, Pietropaolo V, Vullo V, Ciardi MR. 2013. HIV-associated progressive multifocal leukoencephalopathy:longitudinal study of JC virus non-coding control region rearrangements and host immunity. J. Neurovirol. 19:274-279.
47. Bockaert J, Claeysen S, Becamel C, Dumuis A, Marin P. 2006. Neuronal 5-HT metabotropic receptors:fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 326:553-572.
48. Hoyer D, Martin G. 1997. 5-HT receptor classification and nomenclature:towards a harmonization with the human genome. Neuropharmacology 36:419-428.
49. Miyake A, Mochizuki S, Takemoto Y, Akuzawa S. 1995. Molecular cloning of human 5-hydroxytryptamine3 receptor:heterogeneity in distribution and function among species. Mol. Pharmacol. 48:407-416.
50. Liu CK, Hope AP, Atwood WJ. 1998. The human polyomavirus, JCV, does not share receptor specificity with SV40 on human glial cells. J. Neurovirol. 4:49-58.
51. Liu CK, Atwood WJ. 2001. Propagation and assay of the JC virus. Methods Mol. Biol. 165:9-17.
52. Engel S, Heger T, Mancini R, Herzog F, Kartenbeck J, Hayer A, Helenius A. 2011. Role of endosomes in simian virus 40 entry and infection. J. Virol. 85:4198-4211.
53. Pho MT, Ashok A, Atwood WJ. 2000. JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J. Virol. 74:2288-2292.
54. Maginnis MS, Forrest JC, Kopecky-Bromberg SA, Dickeson SK, Santoro SA, Zutter MM, Nemerow GR, Bergelson JM, Dermody TS. 2006. Beta1 integrin mediates internalization of mammalian reovirus. J. Virol. 80:2760-2770.
55. Skehel JJ, Wiley DC. 2000. Receptor binding and membrane fusion in virus entry:the influenza hemagglutinin. Annu. Rev. Biochem. 69:531-569.
56. Stergiou L, Bauer M, Mair W, Bausch-Fluck D, Drayman N, Wollscheid B, Oppenheim A, Pelkmans L. 2013. Integrin-mediated signaling induced by simian virus 40 leads to transient uncoupling of cortical actin and the plasma membrane. PLoS One 8:e55799. doi:10.1371/journal.pone.0055799.
57. Drayman N, Glick Y, Ben-Nun-Shaul O, Zer H, Zlotnick A, Gerber D, Schueler-Furman O, Oppenheim A. 2013. Pathogens use structural mimicry of native host ligands as a mechanism for host receptor engagement. Cell Host Microbe 14:63-73.
58. Sourisseau M, Michta ML, Zony C, Israelow B, Hopcraft SE, Narbus CM, Parra Martin A, Evans MJ. 2013. Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS Pathog. 9:e1003244. doi:10.1371/journal.ppat.1003244.
59. Benedicto I, Molina-Jimenez F, Bartosch B, Cosset FL, Lavillette D, Prieto J, Moreno-Otero R, Valenzuela-Fernandez A, Aldabe R, Lopez-Cabrera M, Majano PL. 2009. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J. Virol. 83:8012-8020.
60. Barton ES, Forrest JC, Connolly JL, Chappell JD, Liu Y, Schnell FJ, Nusrat A, Parkos CA, Dermody TS. 2001. Junction adhesion molecule is a receptor for reovirus. Cell 104:441-451.
61. Raff AB, Woodham AW, Raff LM, Skeate JG, Yan L, Da Silva DM, Schelhaas M, Kast WM. 2013. The evolving field of human papillomavirus receptor research:a review of binding and entry. J. Virol. 87:6062-6072.
62. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75:1565-1570.
63. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M. 2003. Further evidence that papillomavirus capsids exist in two distinct conformations. J. Virol. 77:12961-12967.
64. 2A) receptor function:ligand-dependent mechanisms and pathways, p 105-132. In A Chattopadhyay (ed), Serotonin receptors in neurobiology. CRC Press, Boca Raton, FL.
65. Raote I, Bhattacharyya S, Panicker MM. 2013. Functional selectivity in serotonin receptor 2A (5-HT2A) endocytosis, recycling, and phosphorylation. Mol. Pharmacol. 83:42-50.
66. Querbes W, Benmerah A, Tosoni D, Di Fiore PP, Atwood WJ. 2004. A JC virus-induced signal is required for infection of glial cells by a clathrinand eps15-dependent pathway. J. Virol. 78:250-256.
67. Paspalas CD, Rakic P, Goldman-Rakic PS. 2006. Internalization of D2 dopamine receptors is clathrin-dependent and select to dendro-axonic appositions in primate prefrontal cortex. Eur. J. Neurosci. 24:1395-1403.
68. Kabbani N, Levenson R. 2007. A proteomic approach to receptor signaling:molecular mechanisms and therapeutic implications derived from discovery of the dopamine D2 receptor signalplex. Eur. J. Pharmacol. 572:83-93.
69. Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM. 1995. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products:comparison with 5-HT2A and 5-HT2C receptors. Br. J. Pharmacol. 115:622-628.
70. Monti JM. 2011. Serotonin control of sleep-wake behavior. Sleep Med. Rev. 15:269-281.
71. Singh SP, Singh V, Kar N, Chan K. 2010. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia:meta-analysis. Br. J. Psych. 197:174-179.
72. Lasso M, Ceron I. 2012. Mirtazapine and antiretroviral therapy in the treatment of progressive multifocal leukoencephalopathy associated with HIV-1 infection:report of a case and review of literature. Rev. Chilena Infectol. 29:217-220. [In Spanish.]